Anti-CALCA/CALCB (Eptinezumab), Humanized Antibody

Anti-CALCA/CALCB (Eptinezumab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a fully humanized monoclonal antibody that targets alpha and beta isoforms of calcitonin gene-related peptide (CALCA and CALCB). Calcitonin gene-related peptide (CGRP) is a neuropeptide that is released by the nerve endings of nociceptive (trigeminal) neurons. In addition to dilating meningeal vessels, CGRP causes extravasation of plasma protein and degranulation of mast cells. Degranulation of mast cells releases pro-inflammatory cytokines and causes neurogenic inflammation. Inflammation promotes sensitization of trigeminal neurons that carry the pain stimuli to the thalamus, hypothalamus, and cortex, thus resulting in migraine attacks. The antibody targets both CALCA and CALCB by inhibiting their binding to the receptor thus preventing migraine attacks. The original monoclonal antibody has been approved by the FDA to treat migraines in adults.

Immunogen Sequence:Human CALCA/CALCB

Target Alternative Name:ALD403, CT, KC, PCT, CGRP, CALC1, CGRP1, CGRP-I, CGRP-alpha, CALC2, CGRP2, CGRP-II

Species Reactivities:Human

Tag Line:The biosimilar is a fully humanized monoclonal antibody that targets CALCA and CALCB by blocking their binding to the receptor and prevent migraine attacks

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.